Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1059314 | 0.88 | TLR7 (0.48) | TLR7TLR8 | |
| SCHEMBL1007823 | 0.87 | TLR7 (0.54) | TLR7 | |
| SCHEMBL1062272 | 0.87 | TLR7 (0.61) | TLR7 | |
| SCHEMBL1008316 | 0.86 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL1060545 | 0.86 | TLR7 (0.51) | TLR7 | |
| SCHEMBL1007004 | 0.86 | TLR7 (0.44) | TLR7TLR8 | |
| SCHEMBL1008248 | 0.84 | TLR7 (0.51) | TLR7TLR8KDM4EALDH1A1HPGD | |
| SCHEMBL1010258 | 0.84 | ABCB1 (0.44) | TLR7TLR8 | |
| SCHEMBL1007216 | 0.84 | TLR7 (0.61) | TLR7 | |
| SCHEMBL1008019 | 0.83 | TLR7 (0.49) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190021989-A1 | GALENIC FORMULATION COMPRISING A TOPICAL DRUG | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| WO-2016116886-A1 | GALENIC FORMULATION COMPRISING A TOPICAL DRUG | NOVARTIS AG (CH) | 2016-07-28 | — | — | WO | disclosed |
| EP-2558069-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | Novartis AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130379-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | NOVARTIS AG (CH) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190021989-A1 | GALENIC FORMULATION COMPRISING A TOPICAL DRUG | TLR7, GALR1, GALR2 | TLR7 1/4885TLR8 19/4885PDE10A 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.